Health Condition 1: B359- Dermatophytosis, unspecified
Conditions
Interventions
Intervention1: Tablet Terbinafine 250mg oral OD,
Tablet Levocetrizine 5mg oral BD and
Topical Clotrimazole cream local application BD: Medications prescribed are conventional oral and topical antifung
Sponsors
GCS Medical College Hospital and Research Centre
Eligibility
Inclusion criteria
Inclusion criteria: 1)Patients of either sex age between 18 to 60 years. 2)Presence fungus in scrapping taken from lesion by in KOH preparation. 3)Women of child bearing age must have a negative urine pregnancy test. 4)Patient willing to give written informed consent for study Exclusion criteria.
Exclusion criteria
Exclusion criteria: 1)Patient less than 18 years age and more than 60 years. 2)Pre-existing Cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, musculoskeletal, neurological or psychiatric disease. 3)Major surgical or medical illness in last 4 weeks before screening. 4)Any concomitant medication for purpose other than dermatophytosis management at presentation or within last 4 weeks before screening. 5)Any concomitant intake of herbal, homeopathic or other alternative therapy at presentation or within last 4 weeks before screening. 6)Alcohol dependence, alcohol abuse or drug abuse within past one year. 7)Moderate to heavy smoking ( >10 cigarettes/day) or consumption of tobacco products 8)Clinically significant illness within 4 weeks before the start of the study 9)Asthma, urticaria or other allergic type reactions after taking any medication 10)Past History of atopy, Family history of atopy in first degree relatives. 11)Pregnant and lactating women 12)Patient having pre-existing medical condition (DM HT or any other medical condition requiring concomitant medicine.) or diagnosed during screening. 13)Clinically diagnosed as dermatophytic skin infection but negative for fungus in KOH examination. 14)Dermatophytosis independently or concomitantly involving scalp (T. Capitis), nail (onychomycosis), palm (T. pedis) and sole (T. mannum). 15)Patients having skin lesions with secondary bacterial infections. 16)Past or present history of atopy including any type of eczema, H/o contact sensitization, Allergic rhinitis or Asthma. 17)HIV Hepatitis B, C positive patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -To study clinical cure rate by achieving grade 3 in grades of improvement and grade 4 in physician global assesement of disease activity in patient of dermatophytosis and itâ??s association with pre and post total serum IgE . - To study mycological cure rate by achieving KOH mount negative at end of 2 months -To study relapse rate of clinical and mycological relapse rate in patient with dermatophytosis at end of 2 months and itâ??s association with pre and post total serum IgETimepoint: 2 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To check the association of study parameters with other clinical parameters like prior use of topical and systemic steroids and its association with seum Ig E.Timepoint: 1 year | — |
Countries
India
Contacts
Public ContactDr Vidhi S Chandibhamar
GCS Medical college, hospital and research center
Outcome results
None listed